Shots:

• The P-III PROpel study evaluated the efficacy, safety, and tolerability of Lynparza + abiraterone vs abiraterone alone in men with mCRPC who had not received prior CT or NHAs in 1L setting
• In a predefined interim analysis, study showed 34% reduction in the risk of disease progression or death, mrPFS (24.8mos. vs 16.6mos.), improvement in OS but did not reach statistical significance. The results showed benefits in patients irrespective of homologous recombination repair gene mutations
• The combination regimen was well tolerated and allowed patients to maintain their quality of life

 Ref: AstraZeneca | Image: PMLiVe